Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-08-01FDA Approved: DETROL LA — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DETROL LA (tolterodine tartrate) from Viatris Specialty LLC.
-
FDA approval · 2012-08-01FDA Approved: TOLTERODINE TARTRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for tolterodine tartrate submitted by Mylan Pharmaceuticals Inc. under NDA 020771. The drug is a tre…
-
FDA approval · 2012-08-01FDA Approved: TOVIAZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for TOVIAZ (fesoterodine fumarate) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS withdrawal · 2012-07-24Clinical Trial Update: Overactive Bladder (OAB) Drink Advice Study [NA]
The Overactive Bladder Drink Advice Study sponsored by Radboud University Medical Center has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2012-07-19Clinical Trial Update: Urgent-SQ in Treatment of Overactive Bladder Syndrome: 9-yr Follow up
This document reports a 9-year follow-up of Urgent-SQ for the treatment of overactive bladder, focusing on long-term outcomes and safety.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2012-07-13FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for Vesicare (solifenacin succinate) submitted by Astellas Pharma US, updating the labeling for …
-
CLINICAL_TRIALS trial_result · 2012-07-13Clinical Trial Update: A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder [Phase 1]
A Phase 1 randomized, placebo-controlled trial is evaluating the efficacy of propantheline to treat overactive bladder associated with HTLV-…
-
CLINICAL_TRIALS trial_result · 2012-07-09Clinical Trial Update: Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).
Pfizer completed a long-term post-marketing safety investigation of tolterodine for overactive bladder; results were posted in 2012.
-
FDA approval · 2012-06-28FDA Approved: MYRBETRIQ — Original Application (Astellas Pharma US, Inc.)
FDA approved Mirabegron (Myrbetriq) from Astellas Pharma US for the original application, marking the initial approval for this product to t…
-
CLINICAL_TRIALS trial_result · 2012-06-14Clinical Trial Update: Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Clinical trial update for tolterodine as part of a post-marketing commitment; study on overactive bladder completed with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2012-06-14Clinical Trial Update: Study of ONO-8539 in Patients With Overactive Bladder [Phase 2]
This entry reports the completion of a Phase 2 trial evaluating ONO-8539 in patients with overactive bladder.
-
FDA approval · 2012-06-13FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Strides Pharma Science Limited)
The FDA approved a supplemental application for oxybutynin chloride submitted by Strides Pharma Science Limited.
-
CLINICAL_TRIALS trial_result · 2012-06-13Clinical Trial Update: Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder [Phase 3]
This Phase 3 trial assesses the long-term safety and efficacy of imidafenacin in adults with overactive bladder; the study has been complete…
-
FDA approval · 2012-06-13FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for oxybutynin chloride filed by Teva Pharmaceuticals USA, Inc., encompassing a labeling change thro…
-
FDA label_change · 2012-06-07FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for Vesicare (solifenacin succinate) filed by Astellas Pharma US, Inc., resulting in a label change.
-
FDA approval · 2012-05-31FDA Approved: TROSPIUM CHLORIDE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved a supplemental application for trospium chloride filed by Glenmark Pharmaceuticals Inc., USA, supporting a labeling change …
-
CLINICAL_TRIALS trial_result · 2012-05-30Clinical Trial Update: Feasibility of "At-home" Titration of Solifenacin [Phase 4]
Phase 4 study evaluating the feasibility of at-home titration of solifenacin for overactive bladder; the trial was terminated and results we…
-
CLINICAL_TRIALS trial_result · 2012-05-16Clinical Trial Update: Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms [NA]
This clinical trial compares solifenacin succinate with fesoterodine for urgency symptoms in overactive bladder. The status is unknown.
-
CLINICAL_TRIALS trial_result · 2012-05-02Clinical Trial Update: InterStim Therapy Programming Study [NA]
Completed clinical trial evaluating InterStim Therapy programming; results were posted in 2012.
-
FDA approval · 2012-04-26FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for oxybutynin chloride from Upsher-Smith Laboratories, likely updating labeling or indications.
-
FDA approval · 2012-04-26FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Strides Pharma Science Limited)
The FDA approved a supplemental application for oxybutynin chloride from Strides Pharma Science Limited. This action approves the generic pr…
-
CLINICAL_TRIALS trial_result · 2012-04-16Clinical Trial Update: Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder [Phase 4]
A Phase 4 clinical trial comparing the efficacy and safety of imidafenacin versus fesoterodine in adults with overactive bladder.
-
CLINICAL_TRIALS research · 2012-04-02Clinical Trial Update: Painless Laser Therapy for Overactive Bladder [NA]
An update on a clinical trial evaluating painless laser therapy for overactive bladder; the status is unknown.
-
CLINICAL_TRIALS trial_result · 2012-03-15Clinical Trial Update: This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder
An open-label study evaluating fesoterodine plus a patient support plan in patients with overactive bladder has completed with results poste…
-
CLINICAL_TRIALS research · 2012-03-05Clinical Trial Update: Investigation of the Suburothelial Myofibroblast Network and of Smooth Muscle Function and Control in the Human Urinary Outflow Tract
This entry describes an ongoing clinical trial from Ludwig-Maximilians-University Munich. It investigates the suburothelial myofibroblast ne…